MARKET

IRWD

IRWD

Ironwood
NASDAQ
3.965
-0.205
-4.92%
Opening 12:59 05/12 EDT
OPEN
4.080
PREV CLOSE
4.170
HIGH
4.105
LOW
3.931
VOLUME
953.07K
TURNOVER
--
52 WEEK HIGH
5.78
52 WEEK LOW
0.5271
MARKET CAP
652.69M
P/E (TTM)
6.78
1D
5D
1M
3M
1Y
5Y
1D
Results: Ironwood Pharmaceuticals, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Simply Wall St · 1d ago
Weekly Report: what happened at IRWD last week (0504-0508)?
Weekly Report · 1d ago
Ironwood Pharmaceuticals Q1 Earnings Call Highlights
NASDAQ · 4d ago
Ironwood Pharmaceuticals (IRWD) Q1 Profit Of US$40.8 Million Tests Bearish Earnings-Decline Narrative
Simply Wall St · 4d ago
Ironwood reiterates 2026 LINZESS guidance of $1.125B-$1.175B as STARS-2 initiation nears
Seeking Alpha · 4d ago
Ironwood reports Q1 EPS 24c, consensus 24c
TipRanks · 5d ago
Ironwood affirms FY26 revenue $450M-$475M, consensus $458.6M
TipRanks · 5d ago
Best Small Cap Value Stocks May 2026
Seeking Alpha · 5d ago
More
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.

Webull offers Ironwood Pharmaceuticals, Inc. stock information, including NASDAQ: IRWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRWD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRWD stock methods without spending real money on the virtual paper trading platform.